Floatz logo

SACUBITRIL VALSARTAN

Neoplasm, Breast

Silesian Centre for Heart DiseasesSmall moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

176 Active assets in the Neoplasm, Breast cohort.

Asset / SponsorPhaseRating
EXEMESTANE
Fujian Cancer Hospital
Phase 4BB
Letrozole
Fujian Cancer Hospital
Phase 4BB
Cyclophosphamide
Merck Sharp & Dohme LLC
Phase 4BB
Inno-206
Merck Sharp & Dohme LLC
Phase 4BB
TAMOXIFEN
Eli Lilly and Company
Phase 3BB

View all 50 →

Same molecule, other indications

SACUBITRIL VALSARTAN is also rated in:

Impaired Glucose ToleranceDormant
BB
Indicative ·
65 / 100
View asset →
Blood PressureDormant
BB
Indicative ·
65 / 100
View asset →
breast disorderDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →